IoM chaparral monograph
This article was originally published in The Tan Sheet
Executive Summary
Institute of Medicine will meet Aug. 30-31 to discuss its chaparral draft monograph, the first prototype monograph developed as part of institute's Proposed Framework for Evaluating the Safety of Dietary Supplements. Under the framework, monographs will be prepared on supplements selected for safety review to help guide further FDA action ("1The Tan Sheet" July 29, 2002, p. 4). The 2chaparral monograph, which does not reach safety conclusions, will be discussed in public session the afternoon of Aug. 30. Written comments will be accepted...
You may also be interested in...
Three-Step Supplement Safety Review Model Proposed by IoM
Outside review organizations could play a key role in preparing dietary supplement safety monographs as part of the Institute of Medicine's Proposed Framework for Evaluating the Safety of Dietary Supplements
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.